Insmed Incorporated will present data from its New Drug Application for Somatokine (rhIGF-I/rhIGFBP-3) (mecasermin rinfibate) for the treatment of Growth Hormone Insensitivity Syndrome (GHIS) on September 23 at the European Society Paediatric Endocrinology/ Lawson Wilkins Paediatric Endocrine Society 7th Joint Meeting, a global meeting of paediatric endocrinologists.

GHIS encompasses a variety of genetic and acquired conditions in which the action of growth hormone (GH) is absent or severely attenuated, resulting in low serum levels of IGF-I. Because IGF-I is the primary mediator of the growth-promoting actions of GH, SomatoKine replacement therapy in children with GHIS is intended to bypass the blocked actions of GH by replacing the deficient IGF-I, resulting in improved growth.

Insmed's SomatoKine is a proprietary drug product for the delivery of recombinant insulin-like growth factor I (IGF-I). It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3 (rhIGFBP-3). In the bound state, the IGF-I is inactive, and remains so until delivered to target tissues in the body where it is released and becomes biologically active. This reduces the risk of short- and long-term safety concerns that have been associated with unrestrained levels of free IGF-I, according to a company release.